Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
273.69 -1.30   -0.47%1,359,2641.8M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 03:59 PM ET 5/2/2016

Latest News Headlines for Biogen Inc

Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA(TM) (Daclizumab) for Treatment of Multiple Sclerosis

- Positive Benefit-Risk Profile of ZINBRYTA Supported by Large Head-to-Head Phase 3 DECIDE Study - CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--April 29, 2016-- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for ZINBRYTA(TM) (daclizumab) intended for the treatment of relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered, subcutaneous investigational treatment for RMS. ZINBRYTA is also currently under regulatory review in the United States, Switzerland, Canada and Australia.

Biogen Appoints Michael Ehlers Executive Vice President, Research and Development

Will Lead Company's Efforts to Create Transformational Medicines CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 27, 2016-- Biogen (NASDAQ: BIIB) today announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open274.74
Previous Close274.99
Day High274.99
Day Low268.883
52 Week High6/23/2015 | 420.99
52 Week Low2/12/2016 | 242.07
% Off 52 Week High-34.99%
% Off 52 Week Low13.06%
Beta (5 Yr)0.8
Volatility Avg4/29/2016 | 40.51
10-Day Avg. Volume1,809,966
Market data is delayed by at least 15 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)3/31/2016 | 16.28
P/E Ratio3/31/2016 | 16.9
Market CapLarge Cap | 60.0B
Shares Outstanding219.05M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.12M
Short Ratio1.1
Short % of Float0.97%
As of 4/15/2016